AXS-05 consists of dextromethorphan, an NMDA receptor antagonist, and bupropion, a norepinephrine and dopamine reuptake inhibitor. The Food and Drug Administration (FDA) has granted Priority Review to ...
Shares of Axsome Therapeutics (AXSM) surged this week after the company reported positive phase 2 results of AXS-05 in MDD. The trial showed a clear separation of AXS-05 and active control bupropion, ...
NEW YORK, April 26, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results